FdaApplication
NDA 212937
Identifiers
- fda_app_no: NDA212937
Properties
| Property | Value |
|---|---|
| applicant_name | FENNEC PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2022-09-20 |
Revenue by product
PEDMARK
| Period | Revenue |
|---|---|
| Q1 2026 | $15.1M |
| Q4 2025 | $13.8M |
| Q3 2025 | $12.5M |
| Q2 2025 | $9.7M |
| Q1 2025 | $8.8M |
| Q4 2024 | $7.9M |
| Q3 2024 | $7.0M |
| Q2 2024 | $7.3M |
| Q1 2024 | $7.4M |
| Q4 2023 | $8.7M |
| Q3 2023 | $6.9M |
| Q2 2023 | $3.3M |
| Q1 2023 | $1.7M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| PEDMARK | SODIUM THIOSULFATE | 12.5GM/100ML (125MG/ML) | SOLUTION;INTRAVENOUS |
1 product